BRPI0816154A2 - Moduladores canabinóides de 5-vinilfenil-1-fenil-pirazol substituídos - Google Patents
Moduladores canabinóides de 5-vinilfenil-1-fenil-pirazol substituídosInfo
- Publication number
- BRPI0816154A2 BRPI0816154A2 BRPI0816154-2A2A BRPI0816154A BRPI0816154A2 BR PI0816154 A2 BRPI0816154 A2 BR PI0816154A2 BR PI0816154 A BRPI0816154 A BR PI0816154A BR PI0816154 A2 BRPI0816154 A2 BR PI0816154A2
- Authority
- BR
- Brazil
- Prior art keywords
- vinylphenyl
- phenyl
- replaced
- cannabinoid modulators
- pyrazole cannabinoid
- Prior art date
Links
- QGYYSNGCTSJNCG-UHFFFAOYSA-N 3-(3-ethenylphenyl)-1-phenylpyrazole Chemical compound C=CC1=CC=CC(C2=NN(C=C2)C=2C=CC=CC=2)=C1 QGYYSNGCTSJNCG-UHFFFAOYSA-N 0.000 title 1
- 229930003827 cannabinoid Natural products 0.000 title 1
- 239000003557 cannabinoid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95541107P | 2007-08-13 | 2007-08-13 | |
| PCT/US2008/072846 WO2009023653A2 (en) | 2007-08-13 | 2008-08-12 | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0816154A2 true BRPI0816154A2 (pt) | 2015-02-18 |
Family
ID=40351436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816154-2A2A BRPI0816154A2 (pt) | 2007-08-13 | 2008-08-12 | Moduladores canabinóides de 5-vinilfenil-1-fenil-pirazol substituídos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7943653B2 (pt) |
| EP (1) | EP2192900A4 (pt) |
| JP (1) | JP2011504167A (pt) |
| KR (1) | KR20100052532A (pt) |
| CN (1) | CN101969945A (pt) |
| AU (1) | AU2008286976A1 (pt) |
| BR (1) | BRPI0816154A2 (pt) |
| CA (1) | CA2696006A1 (pt) |
| MX (1) | MX2010001714A (pt) |
| NZ (1) | NZ583389A (pt) |
| RU (1) | RU2010109369A (pt) |
| WO (1) | WO2009023653A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
| US8227461B2 (en) * | 2009-04-30 | 2012-07-24 | Hoffmann-La Roche Inc. | Isoxazoles |
| AU2010244552A1 (en) * | 2009-05-05 | 2011-09-29 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| US8859606B2 (en) | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| BR102017010169A2 (pt) * | 2017-05-15 | 2019-02-26 | Remer Consultores Assessoria Empresarial Ltda. | composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante |
| WO2020123855A1 (en) | 2018-12-12 | 2020-06-18 | University Of Washington | Inhibitor compounds for male contraception |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2948718A (en) * | 1960-08-09 | New n-heterocyclic compounds | ||
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DK153787C (da) * | 1979-06-01 | 1989-01-16 | Wellcome Found | Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved |
| LU83729A1 (fr) * | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| BR8707672A (pt) * | 1987-01-05 | 1989-10-03 | Du Pont | Pirazolinas inseticidas |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US6331555B1 (en) * | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
| CA2387138A1 (en) * | 1999-10-18 | 2001-04-26 | University Of Connecticut | Cannabimimetic indole derivatives |
| EP1735286B1 (en) * | 2004-03-24 | 2012-01-04 | Janssen Pharmaceutica NV | Tetrahydro-indazole cannabinoid modulators |
| JP2009508954A (ja) * | 2005-09-23 | 2009-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換3−アミド−テトラヒドロ−インダゾリル系カンナビノイドモジュレーター |
| BRPI0616263A2 (pt) * | 2005-09-23 | 2011-06-14 | Janssen Pharmaceutica Nv | moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol |
| US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
-
2008
- 2008-08-11 US US12/189,230 patent/US7943653B2/en not_active Expired - Fee Related
- 2008-08-12 AU AU2008286976A patent/AU2008286976A1/en not_active Abandoned
- 2008-08-12 BR BRPI0816154-2A2A patent/BRPI0816154A2/pt not_active IP Right Cessation
- 2008-08-12 JP JP2010521114A patent/JP2011504167A/ja active Pending
- 2008-08-12 EP EP08797659.3A patent/EP2192900A4/en not_active Withdrawn
- 2008-08-12 CN CN2008801056806A patent/CN101969945A/zh active Pending
- 2008-08-12 KR KR1020107005405A patent/KR20100052532A/ko not_active Withdrawn
- 2008-08-12 RU RU2010109369/04A patent/RU2010109369A/ru not_active Application Discontinuation
- 2008-08-12 NZ NZ583389A patent/NZ583389A/en not_active IP Right Cessation
- 2008-08-12 WO PCT/US2008/072846 patent/WO2009023653A2/en not_active Ceased
- 2008-08-12 CA CA2696006A patent/CA2696006A1/en not_active Abandoned
- 2008-08-12 MX MX2010001714A patent/MX2010001714A/es active IP Right Grant
-
2011
- 2011-04-04 US US13/079,114 patent/US20110178148A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008286976A1 (en) | 2009-02-19 |
| KR20100052532A (ko) | 2010-05-19 |
| US7943653B2 (en) | 2011-05-17 |
| CA2696006A1 (en) | 2009-02-19 |
| WO2009023653A2 (en) | 2009-02-19 |
| US20090048235A1 (en) | 2009-02-19 |
| JP2011504167A (ja) | 2011-02-03 |
| WO2009023653A3 (en) | 2012-06-21 |
| NZ583389A (en) | 2012-07-27 |
| RU2010109369A (ru) | 2011-09-20 |
| US20110178148A1 (en) | 2011-07-21 |
| MX2010001714A (es) | 2010-03-10 |
| EP2192900A2 (en) | 2010-06-09 |
| EP2192900A4 (en) | 2013-04-10 |
| CN101969945A (zh) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813653A2 (pt) | Compostos de imidazotiazol moduladores de sirtuína | |
| BRPI0813651A2 (pt) | Compostos de tiazolopiridina moduladores de sirtuína | |
| BR112012008159A2 (pt) | moduladores de receptor canabinoide | |
| BRPI0818380A2 (pt) | Combinação de herbicida-protetor | |
| EP2170350A4 (en) | SUBSTITUTED IMIDAZOHETEROCYCLES | |
| ATE542825T1 (de) | Substituierte piperidino-dihydrothienopyrimidine | |
| FI20075862A0 (fi) | Jauhin | |
| ATE501136T1 (de) | Imidazopyridinone | |
| BRPI0819093A2 (pt) | compostos moduladores de sirtuína | |
| BRPI0813230A2 (pt) | Moduladores de calicreína 7 | |
| BRPI0811939A2 (pt) | Tiazóis substituídos por heteroarila | |
| CU23870B1 (es) | Derivados de ciclopropilamida como moduladores h3 | |
| EP1841794A4 (en) | MODULATORS ADAM-9 | |
| EP2217589A4 (en) | MODULATORS OF OCULAR OXIDATIVE STRESS | |
| AT505058A3 (de) | Türschliesssystem | |
| BRPI0822061A2 (pt) | Moduladores do receptor canabinoide | |
| BRPI0816154A2 (pt) | Moduladores canabinóides de 5-vinilfenil-1-fenil-pirazol substituídos | |
| BRPI0810195A2 (pt) | Moduladores de gpbar1 | |
| EP2198082A4 (en) | REFINER | |
| ATE475602T1 (de) | AUSGIEßER | |
| EP2227553A4 (en) | Lac expression system | |
| DK2147106T3 (da) | Expressionssystem | |
| BRPI0819359A2 (pt) | Unidade de embalagem | |
| IL200957A0 (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
| EP1915162A4 (en) | Modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |